| Drug Name |
Floxuridine |
| Drug ID |
BADD_D00908 |
| Description |
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. |
| Indications and Usage |
For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion). |
| Marketing Status |
approved |
| ATC Code |
L01BC09 |
| DrugBank ID |
DB00322
|
| KEGG ID |
D04197
|
| MeSH ID |
D005467
|
| PubChem ID |
5790
|
| TTD Drug ID |
D0TS1Z
|
| NDC Product Code |
63323-145; 0143-9270; 81643-9270; 59605-5352 |
| UNII |
039LU44I5M
|
| Synonyms |
Floxuridine | 5-FUdR | FUdR | Fluorodeoxyuridine | 5-Fluorodeoxyuridine | 5 Fluorodeoxyuridine |
